Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to Hold

TD Securities lowered shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a buy rating to a hold rating in a report issued on Tuesday morning,BayStreet.CA reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a research report on Friday, March 28th.

Milestone Pharmaceuticals Trading Down 5.0 %

Shares of MIST stock opened at $0.76 on Tuesday. The company has a market capitalization of $40.55 million, a PE ratio of -0.94 and a beta of 1.83. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 12-month low of $0.72 and a 12-month high of $2.75. The firm has a 50 day moving average price of $1.95 and a two-hundred day moving average price of $1.83.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp grew its stake in shares of Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after acquiring an additional 10,000 shares in the last quarter. National Bank of Canada FI lifted its position in shares of Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after buying an additional 11,600 shares during the last quarter. PVG Asset Management Corp bought a new position in Milestone Pharmaceuticals in the 3rd quarter worth approximately $46,000. Cubist Systematic Strategies LLC purchased a new position in shares of Milestone Pharmaceuticals in the fourth quarter valued at $73,000. Finally, XTX Topco Ltd purchased a new position in Milestone Pharmaceuticals during the 4th quarter valued at about $80,000. 86.18% of the stock is owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.